TABLE 4.
Summary of Xpert Carba-R performance for different carbapenemase targets versus that of the reference method (culture plus sequencing) for combined clinical and contrived specimens
| Target gene | Sensitivity (% [95% CI]) | Specificity (% [95% CI]) | PPV (%) | NPV (%) |
|---|---|---|---|---|
| IMP-1 | 96.3 (81.0–99.9) | 100 (99.4–100) | 100 | 99.8 |
| VIM | 93.5 (78.6–99.2) | 99.8 (99.1–100) | 96.7 | 99.7 |
| NDM | 100 (86.8–100) | 99.8 (99.1–100) | 96.3 | 100 |
| KPC | 96.7 (82.8–99.9) | 99.3 (98.3–99.8) | 87.9 | 99.8 |
| OXA-48 | 95.0 (83.1–99.4) | 99.8 (99.1–100) | 97.4 | 99.7 |